Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer

Publication date: Available online 15 May 2019Source: Prostaglandins & Other Lipid MediatorsAuthor(s): Vahid Karpisheh, Afshin Nikkhoo, Mohammad Hojjat-Farsangi, Afshin Namdar, Gholamreza Azizi, Ghasem Ghalamfarsa, Mehdi Yousefi, Bahman Yousefi, Farhad Jadidi-NiaraghAbstractAlthough colon cancer is one of the most important triggers of cancer related mortality, a few therapeutic options exist for this disease, including combination chemotherapy, anti-EGFR and anti-angiogenic agents. However, none of these therapeutics are fully effective for complete remission, and this issue needs further investigations, particularly in the patients with advanced disease. It has been shown that colon carcinogenesis process is associated with upregulation of prostaglandin (PG) levels. Moreover, conversion of pre-malignant cells to malignant was also related with increased generation of PGs in susceptible subjects. Among the prostanoids, PGE2 is the most important produced member which generated in high levels by colon tumor cells. Generation of PGE2 by action of cyclooxygenase (COX)-2 can promote growth and development, resistance to apoptosis, proliferation, invasion and metastasis, angiogenesis and drug resistance in colon cancer. Increased levels of PGE2 and COX-2 in colon cancer is reported by various investigators which was associated with disease progression. It is suggested that there is a positive feedback loop between COX-2 and PGE2, in which function of COX-2 induces generation of P...
Source: Prostaglandins and Other Lipid Mediators - Category: Lipidology Source Type: research